Clinical Trials Browser

INDUSTRY × Recurrence × Panitumumab × Clear all

NCT00454779 2018-10-17

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Phase 2 Completed

113 enrolled 18 charts

Neoplasm Metastasis, Recurrence